4-aminobenzoic acid has been researched along with Diabetic Nephropathies in 5 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Type 2 diabetes was induced in adult male rats by high-fructose/high-fat diet and low streptozotocin dose." | 1.46 | PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis. ( Ahmed, AF; Ali, AA; El-Bassossy, HM; El-Maraghy, NN; Zakaria, EM, 2017) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease worldwide, but no effective therapeutic strategy is available." | 1.43 | Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model. ( Ha, H; Jeong, BY; Lee, HB; Lee, JH; Miyata, T; Park, JH; Uddin, MJ, 2016) |
| "Microalbuminuria in type 1 diabetes is the earliest manifestation of diabetic microangiopathy (nephropathy)." | 1.40 | Aminaphtone therapy in patients with type 1 diabetes and albuminuria: a case report. ( Bertini, M; Costa, M; Fassari, AL; Messina, M; Romano, C; Tamburella, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wen, S | 1 |
| Deng, F | 1 |
| Li, L | 1 |
| Xu, L | 1 |
| Li, X | 1 |
| Fan, Q | 1 |
| Wang, X | 1 |
| Wu, T | 1 |
| Ma, H | 1 |
| Huang, X | 1 |
| Huang, K | 1 |
| Ye, C | 1 |
| Zhu, S | 1 |
| Romano, C | 1 |
| Tamburella, C | 1 |
| Costa, M | 1 |
| Messina, M | 1 |
| Fassari, AL | 1 |
| Bertini, M | 1 |
| Jeong, BY | 1 |
| Uddin, MJ | 1 |
| Park, JH | 1 |
| Lee, JH | 1 |
| Lee, HB | 1 |
| Miyata, T | 1 |
| Ha, H | 1 |
| Zakaria, EM | 1 |
| El-Maraghy, NN | 1 |
| Ahmed, AF | 1 |
| Ali, AA | 1 |
| El-Bassossy, HM | 1 |
5 other studies available for 4-aminobenzoic acid and Diabetic Nephropathies
| Article | Year |
|---|---|
VX-765 ameliorates renal injury and fibrosis in diabetes by regulating caspase-1-mediated pyroptosis and inflammation.
Topics: Animals; Caspase 1; Cell Culture Techniques; Diabetes Mellitus, Experimental; Diabetic Nephropathies | 2022 |
VX-765 ameliorates inflammation and extracellular matrix accumulation by inhibiting the NOX1/ROS/NF-κB pathway in diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Diabetes Mellitus, Experimental; Diabet | 2022 |
Aminaphtone therapy in patients with type 1 diabetes and albuminuria: a case report.
Topics: Albuminuria; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Male; Middle Aged; para-Amin | 2014 |
Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, A | 2016 |
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Topics: Animals; Benzamides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2017 |